应用诺和锐特充治疗GDM患者64例,观测治疗起点及治疗后8周的空腹血糖(FBG)、餐后2小时血糖(P2hBG)、糖化血红蛋白(HbAlc)、胰岛素敏感性指标HOMA-IR以及胰岛细胞分泌功能指标HOMA-β,并进行比较。结果治疗8周后,GDM患者FBG、P2hBG、HbAlc水平均明显下降(P<0.05),HOMA-IR水平亦显著降低(P<0.05);未见严重低血糖发生。结论诺和锐特充治疗GDM,能有效、安全地控制血糖,并能够恢复患者的胰岛素敏感性。 Sixty-four patients with GDM were treated with Novo-Rui special treatment. The fasting blood glucose (FBG), 2-hour postprandial blood glucose (P2hBG), HbA1c, insulin sensitivity index HOMA-IR and Islet cells secrete function index HOMA-β, and compared. Results After 8 weeks of treatment, the levels of FBG, P2hBG and HbAlc in GDM patients were significantly decreased (P <0.05) and HOMA-IR levels were significantly decreased (P <0.05). No severe hypoglycemia occurred. Conclusion Novo-Rui special treatment of GDM, can effectively and safely control blood sugar, and can restore the patient’s insulin sensitivity.